Regeneron Pharmaceuticals Inc
REGN749.790USD
+3.430+0.46%
Close 12/17, 16:00（ET）Quotes delayed by 15 min
78.95BMarket Cap
17.29P/E TTM
More Details of Regeneron Pharmaceuticals Inc Company
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Regeneron Pharmaceuticals Inc Info
Ticker SymbolREGN
Company nameRegeneron Pharmaceuticals Inc
IPO dateApr 02, 1991
CEOSchleifer (Leonard S)
Number of employees15106
Security typeOrdinary Share
Fiscal year-endApr 02
Address777 Old Saw Mill River Road
CityTARRYTOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10591
Phone17813705000
Websitehttps://www.regeneron.com/
Ticker SymbolREGN
IPO dateApr 02, 1991
CEOSchleifer (Leonard S)
Company Executives of Regeneron Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.11M
+42.02%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
670.48K
-3.59%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
56.41K
+3.71%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
44.85K
+2.47%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
37.73K
+5.04%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
29.89K
-0.06%
Mr. Christopher R. Fenimore
Mr. Christopher R. Fenimore
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
21.78K
+10.31%
Mr. Arthur F. (Art) Ryan
Mr. Arthur F. (Art) Ryan
Independent Director
Independent Director
17.66K
-0.10%
Ms. Marion E. McCourt
Ms. Marion E. McCourt
Executive Vice President - Commercial
Executive Vice President - Commercial
15.51K
+7.93%
Dr. Michael S. Brown, M.D.
Dr. Michael S. Brown, M.D.
Independent Director
Independent Director
12.62K
-0.13%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.11M
+42.02%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
670.48K
-3.59%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
56.41K
+3.71%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
44.85K
+2.47%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
37.73K
+5.04%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
29.89K
-0.06%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Sanofi
1.44B
39.28%
EYLEA
754.30M
20.52%
Bayer
415.00M
11.29%
EYLEA HD
393.20M
10.70%
Libtayo
247.80M
6.74%
Other
421.70M
11.47%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Sanofi
1.44B
39.28%
EYLEA
754.30M
20.52%
Bayer
415.00M
11.29%
EYLEA HD
393.20M
10.70%
Libtayo
247.80M
6.74%
Other
421.70M
11.47%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.71%
BlackRock Institutional Trust Company, N.A.
5.29%
State Street Investment Management (US)
4.54%
Dodge & Cox
4.41%
JP Morgan Asset Management
2.85%
Other
74.20%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.71%
BlackRock Institutional Trust Company, N.A.
5.29%
State Street Investment Management (US)
4.54%
Dodge & Cox
4.41%
JP Morgan Asset Management
2.85%
Other
74.20%
Shareholder Types
Shareholders
Proportion
Investment Advisor
45.11%
Investment Advisor/Hedge Fund
30.91%
Hedge Fund
5.04%
Pension Fund
2.69%
Research Firm
2.61%
Bank and Trust
2.25%
Individual Investor
2.06%
Sovereign Wealth Fund
1.23%
Insurance Company
0.20%
Other
7.90%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
2596
94.26M
91.26%
-4.21M
2025Q2
2585
99.72M
95.69%
-2.03M
2025Q1
2621
99.84M
93.97%
-1.42M
2024Q4
2581
100.17M
93.15%
-475.65K
2024Q3
2505
99.81M
90.67%
-1.99M
2024Q2
2479
100.87M
93.10%
+570.24K
2024Q1
2440
99.77M
92.44%
+388.23K
2023Q4
2406
98.50M
91.94%
-617.06K
2023Q3
2358
98.79M
92.52%
-1.71M
2023Q2
2360
99.25M
92.00%
-1.42M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
9.37M
9%
+14.55K
+0.16%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.67M
5.44%
-75.61K
-1.32%
Jun 30, 2025
State Street Investment Management (US)
4.83M
4.64%
+42.34K
+0.88%
Jun 30, 2025
Dodge & Cox
3.83M
3.67%
+1.50M
+64.64%
Jun 30, 2025
JP Morgan Asset Management
2.82M
2.7%
-1.26M
-30.95%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.47M
2.37%
-4.53K
-0.18%
Jun 30, 2025
Invesco Capital Management (QQQ Trust)
2.17M
2.09%
-7.70K
-0.35%
Aug 31, 2025
Putnam Investment Management, L.L.C.
2.03M
1.95%
+116.30K
+6.08%
Jun 30, 2025
Capital World Investors
1.97M
1.89%
+27.38K
+1.41%
Jun 30, 2025
Loomis, Sayles & Company, L.P.
1.94M
1.86%
+305.09K
+18.65%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ProShares Ultra Nasdaq Biotechnology
6.6%
Invesco Nasdaq Biotechnology ETF
6.55%
Amplify Weight Loss Drug & Treatment ETF
6.4%
iShares Biotechnology ETF
5.9%
Simplify Health Care ETF
5.54%
VanEck Biotech ETF
5.51%
Invesco Biotechnology & Genome ETF
5.4%
iShares Genomics Immunology and Healthcare ETF
4.97%
First Trust NASDAQ Pharmaceuticals ETF
4.36%
First Trust NYSE Arca Biotechnology Index Fund
3.88%
View more
ProShares Ultra Nasdaq Biotechnology
Proportion6.6%
Invesco Nasdaq Biotechnology ETF
Proportion6.55%
Amplify Weight Loss Drug & Treatment ETF
Proportion6.4%
iShares Biotechnology ETF
Proportion5.9%
Simplify Health Care ETF
Proportion5.54%
VanEck Biotech ETF
Proportion5.51%
Invesco Biotechnology & Genome ETF
Proportion5.4%
iShares Genomics Immunology and Healthcare ETF
Proportion4.97%
First Trust NASDAQ Pharmaceuticals ETF
Proportion4.36%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.88%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Feb 04, 2025
REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025
Feb 20, 2025
Mar 20, 2025
Feb 20, 2025
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Regeneron Pharmaceuticals Inc?
The top five shareholders of Regeneron Pharmaceuticals Inc are:
The Vanguard Group, Inc. holds 9.37M shares, accounting for 9.00% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.67M shares, accounting for 5.44% of the total shares.
State Street Investment Management (US) holds 4.83M shares, accounting for 4.64% of the total shares.
Dodge & Cox holds 3.83M shares, accounting for 3.67% of the total shares.
JP Morgan Asset Management holds 2.82M shares, accounting for 2.70% of the total shares.
The Vanguard Group, Inc. holds 9.37M shares, accounting for 9.00% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.67M shares, accounting for 5.44% of the total shares.
State Street Investment Management (US) holds 4.83M shares, accounting for 4.64% of the total shares.
Dodge & Cox holds 3.83M shares, accounting for 3.67% of the total shares.
JP Morgan Asset Management holds 2.82M shares, accounting for 2.70% of the total shares.
What are the top three shareholder types of Regeneron Pharmaceuticals Inc?
The top three shareholder types of Regeneron Pharmaceuticals Inc are:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
How many institutions hold shares of Regeneron Pharmaceuticals Inc (REGN)?
As of 2025Q3, 2596 institutions hold shares of Regeneron Pharmaceuticals Inc, with a combined market value of approximately 94.26M, accounting for 91.26% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -4.43%.
What is the biggest source of revenue for Regeneron Pharmaceuticals Inc?
In FY2025Q2, the Sanofi business generated the highest revenue for Regeneron Pharmaceuticals Inc, amounting to 1.44B and accounting for 39.28% of total revenue.
